+RNAinsight: A Year in Review | Ambry Genetics

Since October 2019, +RNAinsight has revolutionized germline genetic testing for hereditary cancer and has provided clinically actionable results to many patients and families who may have otherwise received a negative or inconclusive result from DNA-only testing. Here are some highlights from the first year.